CCL18 and ovarian cancer: Wang et al 2011 reported CXCL1 to be overexpressed in serum from ovarian cancer patients and a biomarker model including CXCL1, CCL18 and CA125 was shown to discriminate ovarian cancer from benign ovarian tumors and healthy controls with a sensitivity of 92.6% for ovarian cancer together with impressively high specificity of 99% for healthy controls and 94% for benign tumors [38].